Asst. Prof. Hacer KARATAŞ BRISTOW

Personal Information

Email: hacer.karatas@medipol.edu.tr
Web: https://avesis.medipol.edu.tr/hacer.karatas

International Researcher IDs
ScholarID: lXr04vQAAAAJ
ORCID: 0000-0002-7577-0320
Publons / Web Of Science ResearcherID: ISS-5692-2023
ScopusID: 6506871520
Yoksis Researcher ID: 329044

Published journal articles indexed by SCI, SSCI, and AHCI

I. **Synthesis and Anticancer Activity of Novel Indole Derivatives as Dual EGFR/SRC Kinase Inhibitors.**
Olgen S., Biltekin Kaleli S. N., Karaca B. T., Demirel U. U., Bristow H.
Current medicinal chemistry, 2023 (SCI-Expanded)

II. **An economical and practical procedure of favipiravir synthesis for the treatment of Covid-19**
Karatas H., Hanashalshahaby E. H. A., Catal U., Butun Y. E., Kurt E., Gursel S., Kaya A., GÜZEL M.
Chemical Papers, vol.77, no.3, pp.1695-1702, 2023 (SCI-Expanded)

III. **The Pseudo-Natural Product Rhonin Targets RHOGDI**
Akbarzadeh M., Flegel J., Patil S., Shang E., Narayan R., Buchholzer M., Kazemein Jasemi N. S., Grigalunas M., Krzyzanowski A., Abegg D., et al.
Angewandte Chemie - International Edition, vol.61, no.18, 2022 (SCI-Expanded)

IV. **A protein tertiary structure mimetic modulator of the Hippo signalling pathway**
Adihou H., Gopalakrishnan R., Förster T., Guéret S. M., Gasper R., Geschwindner S., Carrillo García C., KARATAŞ BRISTOW H., Pobbati A. V., Vazquez-Chantada M., et al.
Nature Communications, vol.11, no.1, 2020 (SCI-Expanded)

V. **TEAD–YAP Interaction Inhibitors and MDM2 Binders from DNA-Encoded Indole-Focused Ugi Peptidomimetics**
Kunig V. B. K., Potowski M., Akbarzadeh M., Klika Škopić M., dos Santos Smith D., Arendt L., Dormuth I., Adihou H., Andlovic B., KARATAŞ BRISTOW H., et al.
Angewandte Chemie - International Edition, vol.59, no.46, pp.20338-20342, 2020 (SCI-Expanded)

VI. **Discovery of Covalent Inhibitors Targeting the Transcriptional Enhanced Associate Domain Central Pocket**
KARATAŞ BRISTOW H., Akbarzadeh M., Adihou H., Hahne G., Pobbati A. V., Yihui Ng E., Guéret S. M., Sievers S., Pahl A., Metz M., et al.
Journal of Medicinal Chemistry, vol.63, no.20, pp.11972-11989, 2020 (SCI-Expanded)

VII. **Identification of Quinolinols as Activators of TEAD-Dependent Transcription**
Pobbati A. V., Mejuch T., Chakraborty S., KARATAŞ BRISTOW H., Bharath S. R., Guéret S. M., Goy P., Hahne G., Pahl A., Sievers S., et al.
ACS Chemical Biology, vol.14, no.12, pp.2909-2921, 2019 (SCI-Expanded)

VIII. **Real-Time Imaging and Quantification of Peptide Uptake in Vitro and in Vivo**
KARATAŞ BRISTOW H., Maric T., D'Alessandro P. L., Yevtodiyenko A., Vorherr T., Hollingworth G. J., Goun E. A.
ACS Chemical Biology, vol.14, no.10, pp.2197-2205, 2019 (SCI-Expanded)

IX. **The cholesterol transfer protein GRAMD1A regulates autophagosome biogenesis**

Laraia L., Friese A., Corkery D. P., Konstantinidis G., Erwin N., Hofer W., KARATAŞ BRISTOW H., Klewer L., Brockmeyer A., Metz M., et al.
Nature Chemical Biology, vol.15, no.7, pp.710-720, 2019 (SCI-Expanded)

X. **Chemical suppression of specific C-C chemokine signaling pathways enhances cardiac reprogramming**
Guo Y., Lei I., Tian S., Gao W., Hacer K., Li Y., Wang S., Liu L., Wang Z.
Journal of Biological Chemistry, vol.294, no.23, pp.9134-9146, 2019 (SCI-Expanded)

XI. **In Vivo Molecular Bioluminescence Imaging: New Tools and Applications**
Mezzanotte L., van 't Root M., KARATAŞ BRISTOW H., Goun E. A., Löwik C. W.
Trends in Biotechnology, vol.35, no.7, pp.640-652, 2017 (SCI-Expanded)

XII. **Discovery of a Highly Potent, Cell-Permeable Macrocyclic Peptidomimetic (MM-589) Targeting the WD Repeat Domain 5 Protein (WDR5)-Mixed Lineage Leukemia (MLL) Protein-Protein Interaction**
KARATAŞ BRISTOW H., Li Y., Liu L., Ji J., Lee S., Chen Y., Yang J., Huang L., Bernard D., Xu J., et al.
Journal of Medicinal Chemistry, vol.60, no.12, pp.4818-4839, 2017 (SCI-Expanded)

XIII. **MLL1 Inhibition Reprograms Epiblast Stem Cells to Naive Pluripotency**
Zhang H., Gayen S., Xiong J., Zhou B., Shanmugam A. K., Sun Y., KARATAŞ BRISTOW H., Liu L., Rao R. C., Wang S., et al.
Cell Stem Cell, vol.18, no.4, pp.481-494, 2016 (SCI-Expanded)

XIV. **Targeting MLL1 H3K4 Methyltransferase Activity in Mixed-Lineage Leukemia**
Cao F., Townsend E. C., KARATAŞ BRISTOW H., Xu J., Li L., Lee S., Liu L., Chen Y., Ouillette P., Zhu J., et al.
Molecular Cell, vol.53, no.2, pp.247-261, 2014 (SCI-Expanded)

XV. **Structure-based design of high-affinity macrocyclic peptidomimetics to block the menin-mixed lineage leukemia 1 (MLL1) protein-protein interaction**
Zhou H., Liu L., Huang J., Bernard D., KARATAŞ BRISTOW H., Navarro A., Lei M., Wang S.
Journal of Medicinal Chemistry, vol.56, no.3, pp.1113-1123, 2013 (SCI-Expanded)

XVI. **High-affinity, small-molecule peptidomimetic inhibitors of mll1/wdr5 protein-protein interaction**
KARATAŞ BRISTOW H., Townsend E. C., Cao F., Chen Y., Bernard D., Liu L., Lei M., Dou Y., Wang S.
Journal of the American Chemical Society, vol.135, no.2, pp.669-682, 2013 (SCI-Expanded)

XVII. **Synthesis and potent antimicrobial activity of some novel 4-(5,6-dichloro-7H-benzimidazol-2-yl)-N-substituted benzamides**
ÖZDEN M. S., KARATAŞ BRISTOW H., YILDIZ S., GÖKER A. H.
Archiv der Pharmazie, vol.337, no.10, pp.556-562, 2004 (SCI-Expanded)

Articles Published in Other Journals

I. **Targeting Mll1 H3K4 methyltransferase activity to guide cardiac lineage specific reprogramming of fibroblasts**
Liu L., Lei I., KARATAŞ BRISTOW H., Li Y., Wang L., Gnatovskiy L., Dou Y., Wang S., Qian L., Wang Z.
Cell Discovery, vol.2, 2016 (Scopus)

II. **MLL1 and MLL1 fusion proteins have distinct functions in regulating leukemic transcription program**
Xu J., Li L., Xiong J., DenDekker A., Ye A., KARATAŞ BRISTOW H., Liu L., Wang H., Qin Z. S., Wang S., et al.
Cell Discovery, vol.2, 2016 (Scopus)